All Clinical Trials
Below is a list of all clinical trials, conducted by several of our specialty service lines. You may filter the list of trials by clicking the "Department" dropdown menu and selecting the area that you want to view or that pertains to you.
Clicking "Learn More" may either take you to more information about our departments that conduct the research, or to the official clinicaltrials.gov page for more information about the trial.
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
Study # FcGammaRIIa
A Single-Dose, Open-Label, Randomized, Multi-Center, 2-Treatment Crossover Study To Compare The Pharmacodynamics, Pharmacokinetics, Safety, And Tolerability Of Acetylsalicylic Acid Powder For Oral Inhalation With Non-Enteric-Coated Chewable Aspirin In Adu
Study # NCT05625347
Multidisciplinary Approach to Reduce Cardiovascular Health Disparities in the Baltimore Racial Minority Communities (M-BRACE Trial)
Study # M-BRACE Trial
A Study of the ReCor Medical Paradise System in Clinical Hypertension
Study # NCT02649426
A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy parallel-group, 2-arm, Phase 3 study to compare the efficacy of the oral FXIa inhibitor asundexian with apixaban for the prevention of stroke or systemic em
Study # SCFTR-02
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
Study # VICTORION-2 PREVENT
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA trial
Study # NCT05207709 Date Opened: 03/28/2022 Closing Date: 06/18/2032 (All Centers) Principal Investigator: Maitri Kalra, MD
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack (L
Study # NCT05702034 Date Opened: 02/15/2023 Closing Date: 12/09/2026 Principal Investigator: Jennifer Berkeley, MD, PhD Sponsor: Janssen Research & Development
A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain (RESET)
Study # NCT04246281 Date Opened: 06/17/2020 Closing Date: 03/31/2026 Sponsor: SPR Therapeutics
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy (STARSTIM)
Study # NCT04770337 Date Opened: 10/25/2021 Closing Date: 12/31/2024 Sponsor: Neuroelectrics Corporation
Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI)
Study # NCT04957719 Date Opened: 08/14/2021 Closing Date: 08/31/2025 Sponsor: Idorsia Pharmaceuticals Ltd.
ThromboelAstogRaphy Guided Approach to Reduce Recurrent Events in ACS Patients Undergoing Catheter Based Intervention (TARGET-ACS)
Study # TARGET-ACS
A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)” (NCT 04625647)
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)”
A Phase 2 Open-label Study Evaluating the Efficacy and Safety of luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum resistant epithelial ovarian cancer (including Fallopian Tube or Primary Peritoneal Cancers) expressing Folate
Study # GOG 3086 / STRO-002-GM3 Date Opened: 09/21/2023 (Pharma) Principal Investigator: Pallavi Kumar, M.D.
The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and t
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN’S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE
Study # ML43171 Date Opened: 03/30/2023 (Sinai & Kahlert) Principal Investigator: Maitri Kalra, MD
